TY - JOUR
T1 - Mining the mutanome
T2 - Developing highly personalized Immunotherapies based on mutational analysis of tumors
AU - Organizing Committee of the 2013 SITC Workshop on Personalized Immunotherapy
AU - Overwijk, Willem W.
AU - Wang, Ena
AU - Marincola, Francesco M.
AU - Rammensee, Hans Georg
AU - Restifo, Nicholas P.
N1 - Publisher Copyright:
© 2013 Overwijk et al.
PY - 2013
Y1 - 2013
N2 - T cells can mediate remarkable tumor regressions including complete cure in patients with metastatic cancer. Genetic alterations in an individual's cancer cells (the mutanome) encode unique peptides (m-peptides) that can be targets for T cells. The recent advances in next-generation sequencing and computation prediction allows, for the first time, the rapid and affordable identification of m-peptides in individual patients. Despite excitement about the extended spectrum of potential targets in personalized immunotherapy, there is no experience or consensus on the path to their successful clinical application. Major questions remain, such as whether clinical responses to cytokine therapy, T cell transfer, and checkpoint blockade are primarily mediated by m-peptide-specific reactivity, whether m-peptides can be effectively used as vaccines, and which m-peptides are most potently recognized. These and other technological, immunological and translational questions will be explored during a 1-day Workshop on Personalized Cancer Immunotherapy by the Society for Immunotherapy of Cancer, directly before the Annual Meeting, on November 7, 2013 at the National Harbor, MD near Washington, DC.
AB - T cells can mediate remarkable tumor regressions including complete cure in patients with metastatic cancer. Genetic alterations in an individual's cancer cells (the mutanome) encode unique peptides (m-peptides) that can be targets for T cells. The recent advances in next-generation sequencing and computation prediction allows, for the first time, the rapid and affordable identification of m-peptides in individual patients. Despite excitement about the extended spectrum of potential targets in personalized immunotherapy, there is no experience or consensus on the path to their successful clinical application. Major questions remain, such as whether clinical responses to cytokine therapy, T cell transfer, and checkpoint blockade are primarily mediated by m-peptide-specific reactivity, whether m-peptides can be effectively used as vaccines, and which m-peptides are most potently recognized. These and other technological, immunological and translational questions will be explored during a 1-day Workshop on Personalized Cancer Immunotherapy by the Society for Immunotherapy of Cancer, directly before the Annual Meeting, on November 7, 2013 at the National Harbor, MD near Washington, DC.
KW - Checkpoint blockade
KW - Exome
KW - Mutanome
KW - Mutation
KW - Neoantigen
KW - Next-generation sequencing
KW - Omics
KW - Peptide epitope
KW - T lymphocyte
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=84991030590&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991030590&partnerID=8YFLogxK
U2 - 10.1186/2051-1426-1-11
DO - 10.1186/2051-1426-1-11
M3 - Review article
C2 - 24829748
AN - SCOPUS:84991030590
SN - 2051-1426
VL - 1
JO - Journal for immunotherapy of cancer
JF - Journal for immunotherapy of cancer
M1 - 11
ER -